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Abstract
We have previously shown that tetracyclines interact with and reverse the protease resistance of pathological prion protein
extracted from scrapie-infected animals and patients with all forms of Creutzfeldt-Jakob disease, lowering the prion titre and
prolonging survival of cerebrally infected animals. To investigate the effectiveness of these drugs as anti-prion agents Syrian
hamsters were inoculated intramuscularly or subcutaneously with 263K scrapie strain at a 10
24 dilution. Tetracyclines were
injected intramuscularly or intraperitoneally at the dose of 10 mg/kg. A single intramuscular dose of doxycycline one hour
after infection in the same site of inoculation prolonged median survival by 64%. Intraperitoneal doses of tetracyclines every
two days for 40 or 44 days increased survival time by 25% (doxycycline), 32% (tetracycline); and 81% (minocycline) after
intramuscular infection, and 35% (doxycycline) after subcutaneous infection. To extend the therapeutic potential of
tetracyclines, we investigated the efficacy of direct infusion of tetracyclines in advanced infection. Since intracerebroven-
tricular infusion of tetracycline solutions can cause overt acute toxicity in animals, we entrapped the drugs in liposomes.
Animals were inoculated intracerebrally with a 10
24 dilution of the 263K scrapie strain. A single intracerebroventricular
infusion of 25 mg/ 20 ml of doxycycline or minocycline entrapped in liposomes was administered 60 days after inoculation,
when 50% of animals showed initial symptoms of the disease. Median survival increased of 8.1% with doxycycline and 10%
with minocycline. These data suggest that tetracyclines might have therapeutic potential for humans.
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Introduction
Transmissible spongiform encephalopathies are fatal neurode-
generative diseases that cause extensive loss of cerebral neurons
with formation of vacuoles, giving a ‘‘sponge-like’’ appearance to
the tissue. They include several diseases with different causes
(infectious/iatrogenic, sporadic or genetic origin), recognized both
in humans and animals as variations of the same disorder [1,2].
Althoughtheprecisepathogenicmechanismisstillnotunderstood,
prion diseases involve the deposition of aggregates of disease-related
isoforms (PrP
Sc) of a host-encoded protein (PrP
C) in the central
nervous system. During the progression of the disease, a portion of
the a-helix and random coil structure in PrP
C is refolded into a b-
pleated sheet in PrP
Sc, a conformational change that renders PrP
Sc
poorly soluble and resistant to protease digestion [3]. Consequently,
PrP
Sc aggregates accumulate around neurons in affected brain areas,
a process thought to lead to neuronal dysfunction and death, and
subsequently the clinical symptoms of infection.
Many classes of molecules have been screened in experimental
therapy[4–7],some showingpromising anti-prionactivity,butmost
of them suffer the limitation of poor passage through the blood-
brain barrier (BBB) and severe toxicity. Currently, there is no
therapy for prion diseases in humans. Three drugs, pentosan
polysulfate [8,9], quinacrine [10,11] and flupirtrine [12], are
currently used in the clinical management of human prion diseases,
although none of them have yet been proved to be effective,
reinforcing the importance of identifying new treatment strategies.
Based on structural analogies with Congo red, tetrapyrroles and
acridine derivatives we hypothesized that tetracyclines might
interact with PrP
Sc and interfere with PrP amyloid formation [13].
These old drugs have well-characterized pharmacological and
safety profiles, low toxicity, and some cross the blood-brain barrier
efficiently when a suitable route of administration is used. In
addition, minocycline and doxycycline have neuroprotective
properties in different neurodegenerative diseases [14] due to
their anti-inflammatory and anti-apoptotic effects.
Our studies indicated that tetracyclines are good candidate anti-
prion drugs. Their ability to bind to fibrillary assemblies,
monomeric and oligomeric forms of PrP peptides, homologous
to residues 82 to 146 (PrP82-146) and 106 to 126 (PrP106-126) of
human PrP, and disrupt peptide aggregates, was previously
reported [13]. NMR spectroscopy indicated that tetracyclines
achieved through-space interactions with the hydrophobic peptide
domains. In cell-free studies the various tetracyclines analogues
showed marked differences in facilitating proteinase K (PK)
digestion of PrP peptides [15,7]. In cell culture studies tetracyclines
inhibited neuronal death and astroglial proliferation induced in
vitro by the PrP peptides [13]. Incubation of 263K scrapie-infected
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inmore than90%reductioninthePK-resistantcoreofPrP
Sc.Itwa s
also reported [16] that these compounds can interact with partially
purified PrP
Sc from patients with the new variant of Creutzfeldt-
Jakob disease, and cattle with bovine spongiform encephalopathy.
In vivo there was significant delay in the onset of clinical signs of
disease and prolonged survival in hamsters injected with 1 mM
tetracycline-pre-treated inocula. When tetracyclines were prein-
cubated with highly diluted scrapie-infected inocula one third of
animals did not develop disease [16]. At the time of the onset of
symptoms in controls PrP
Sc accumulation was less abundant in the
brain of tetracycline-treated animals, as was the severity of
spongiform changes and astrogliosis in the cerebral cortex and
subcortical gray structures [16].
We report the efficacy of tetracycline, doxycycline and
minocycline in prolonging the survival of hamsters infected
intramuscularly (im), subcutaneously (sc) or intracerebrally (ic)
with the 263K scrapie strain and showed that the drugs are also
active when administered at the appearance of the first symptoms.
Results
Effect of tetracyclines following peripheral scrapie
infection
Hamsters were peripherally infected by injecting the 263K
scrapie inocula im and sc at 10
24 dilution. The im approach was
followedtosimulateaiatrogenicrouteofinfectionandthescrouteto
slow the spread of scrapie from the periphery to the central nervous
system. A high dilution of the 263K scrapie strain was used to ensure
a long enough interval to test the effectiveness of the drugs to
interfere with scrapie propagation. A high titre of infectivity resulting
from an administration route facilitating neuroinvasion would have
left little room for any practical in vivo screening of anti-prion drugs.
The first experiment was designed to reconfirm our previous
observations that tetracycline and doxycycline bind selectively to
PrP
Sc and sensitize it to protease hydrolysis [16]. Animals were
infected im and received a single dose of 10 mg/kg of doxycycline
at the same site within 1 hour. Immunohistochemical analysis in
preliminary experiments on im infected terminal animals indicated
that PrP
Sc was evenly distributed in the central nervous and
lymphoreticular systems.
As reported in Figure 1 PrP
Sc accumulated in all brain areas
examined, except for the hippocampus (panel A), in spinal cord
(panel B), in the white pulp of spleen (panel C) and in the Peyer’s
patches (panel D). Figure 1E and Table 1 show that a single dose
of doxycycline significantly (p=0.031) increased median survival
by 64%, from 217 days for controls to 355 days for the treated
group. This protective effect was paralleled by the delayed onset of
clinical signs of disease in all treated animals (data not shown).
After this first experiment we designed studies to investigate the
effectiveness of intraperitoneal (ip) tetracyclines in animals infected
Figure 1. Effect of tetracyclines following peripheral scrapie infection. PrP
Sc immunohistochemistry of brain tissue (A), spinal cord (B),
spleen (C), and Peyer’s patches (D) of hamsters at the terminal stage of disease after intramuscular inoculation of 263K scrapie infected brain
homogenate alone at 10
24 dilution. All samples were counterstained with hematoxylin. The pictures are representative of the immunohistochemical
results for all terminal animals. Magnification scale bar: 1 mm (A), 250 mm (B-C-D). (E) Survival of hamsters injected intramuscularly with a 10
24
dilution of 263K scrapie-infected brain homogenate followed one hour later by a single intramuscular dose of doxycycline (10 mg/kg) at the same
site. Untreated animals (%), Doxycycline (N). (F) Survival of hamsters injected intramuscularly with a 10
24 dilution of 263K scrapie-infected brain
homogenate followed one hour later by an intraperitoneal dose of 10 mg/kg of tetracycline, doxycycline or minocycline, then every 2 days up to
40 days post-infection. Untreated animals (%), Tetracycline (n), Doxycycline, (N), Minocycline (#). (G) Survival of hamsters injected subcutaneously
with a 10
24 dilution of 263K scrapie-infected brain homogenate followed four days later by an intraperitoneal dose of 10 mg/kg of doxycycline, then
every 2 days up to 44 days post-infection. Untreated animals (%), Doxycycline, (N).
doi:10.1371/journal.pone.0001888.g001
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to hamsters one hour after infection then every two days for
40 days. Figure 1F and Table 1 show that both tetracycline and
doxycycline significantly prolonged the median survival of
hamsters, by 32% and 25 %, respectively; infected hamsters had
a median survival of 250 days while tetracycline and doxycycline
increased median survival to 330 (p=0.028) and 312 days
(p=0.032) respectively. A remarkable result was obtained with
minocycline that increased median survival by 81%, from 250 to
453 days (p=0.004).
A protective effect was also observed in hamsters inoculated sc
with 263K scrapie strain homogenate and treated with 10 mg/kg
ip doxycycline from day 4 to day 44. In this experiment
doxycycline was given four days after the 263K inoculum because
of the less efficient spread of infection through subcutaneous
mucous membranes. Figure 1G and Table 1 show that
doxycycline increased median survival by 35%, with a significant
increase of median survival, from 611 to 823 days (p=0.004).
Effect of tetracyclines following intracerebral scrapie
infection
In the light of the results after peripheral infection we set up an
experiment to verify whether tetracyclines prolonged the lifespan
of animals at the onset of clinical symptoms. We tested a novel
approach for tetracycline administration which permitted a more
aggressive treatment schedule in a model of overt prion disease,
i.e. ic inoculation of the 263K scrapie strain followed by
intracereboventricular (icv) infusion of liposome-entrapped drugs.
To overcome the risk of toxicity caused by icv administration of
tetracycline solutions we entrapped the drugs in liposomes. In
preliminary studies liposome-entrapped tetracyclines and empty
liposomes showed no toxicity, indicating that icv infusion could be
used to deliver high local drug concentrations (data not shown).
We also verified the effectiveness of doxycycline-entrapped
liposomes (LipoDoxycycline) to reverse PrP
Sc resistance to PK
action. Figure 2A shows that incubation of the 263K scrapie strain
homogenate with LipoDoxycycline for 24 hours increased the
sensitization to PK hydrolysis to the same extent as an identical
concentration of the free molecule. As expected, empty liposomes
had no such effect.
We also verified that tetracyclines diffuse into the parenchyma
after liposome infusion into the lateral ventricle. To this end, 20 ml
of liposomes containing 25 mg doxycycline were infused icv and
the brain distribution of the drug was determined four days later
by fruorescence microscopy of frozen sections. Doxycycline-
related fluorescence was intense in correspondence with the
ependymal cell layer and subependymal space of the ventricular
system, the leptomeninges and subpial space, and in some
meningeal and parenchymal vessel walls and perivascular space.
Noteworthy, doxycycline fluorescence was also present in brain
parenchyma, partly diffused in the neuropil and partly associated
Table 1. Tetracycline treatment schedules and survival of hamsters infected with 263K scrapie strain.






(days-%) Hazard ratio** p value
Intramuscular 217
Intramuscular Doxycycline Intramuscular 10 mg/kg, 1 hour after
infection
355 138-64 2.95 (1.17–28.48) 0.031
Intramuscular 250
Intramuscular Doxycycline Intraperitoneal 10 mg/kg, 1 hour after
infection and every 2 days
for 40 days
312 62-25 2.43 (1.13–15.70) 0.032
Intramuscular Tetracycline Intraperitoneal 10 mg/kg, 1 hour after
infection and every 2 days
for 40 days
330 80-32 2.49 (1.17–16.29) 0.028
Intramuscular Minocycline Intraperitoneal 10 mg/kg, 1 hour after
infection and every 2 days
for 40 days
453 203-81 3.37 (1.98–34.10) 0.004
Subcutaneous 611
Subcutaneous Doxycycline Intraperitoneal 10 mg/kg, 4 days after
infection and every 2 days
for 44 days
823 212-35 3.14 (1.73–19.10) 0.004
Intracerebral 122
Intracerebral LipoDoxycycline Intracerebroventricular 25 mg/20 ml 30 days after
infection
134 12–9.8 4.624 (1.231–17.37) 0.023
Intracerebral 130
Intracerebral LipoDoxycycline Intracerebroventricular 25 mg/20 ml 60 days after
infection*
140.5 10–8.1 2.34 (1.08–13.26) 0.037
Intracerebral LipoMinocycline Intracerebroventricular 25 mg/20 ml 60 days after
infection*
144 14-10 2.10 (0.94–12.31) 0.063
Liposomes containing doxycycline or minocycline (LipoDoxycycline and LipoMinocycline) were prepared as described in Methods.
*At this time the clinical symptoms of disease appeared in 50% of animals.
**In brackets the 95% confidence interval of the hazard ratio.
doi:10.1371/journal.pone.0001888.t001
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significant fluorescence signals were detected in the brain injected
with empty liposomes.
To explore whether the time of intervention is important in
delaying the disease, in a first experiment LipoDoxycycline
(25 mg/20 ml, icv) was given 30 days after prion inoculation. This
treatment schedule caused a significant (p=0.023) increase of the
median survival of 9.8% (from 122 to 134 days), indicating that
the therapeutic intervention could in fact be postponed (Table 1).
To investigate whether tetracyclines were effective at the onset of
the clinical symptoms associated with prion infection LipoDox-
ycycline or LipoMinocycline (25 mg/20 ml) were infused icv
60 days after ic infection with the 263K scrapie strain when
50% of the animals showed initial symptoms of disease
(hyperreactivity to tactile and acoustic stimulation). Figure 2E
and Table 1 show that both preparation increased the median
survival respectively by 8.1% (from 130 to 140.5 days, p=0.037)
and 10% (from 130 to 144 days, p=0.063).
Discussion
We have previously shown that the mechanism of action of
tetracyclines as anti-prion drugs depends on their effectiveness in
sensitizing PrP
Sc to proteolytic degradation, after binding to
lypophilic domains of the protein, reducing or abolishing prion
infectivity [13,21]. Tetracyclines bind not only to PrP aggregates
but also to neurotoxic peptides, antagonizing their toxic effect on
nerve and glial cells, and inhibiting astroglial proliferation [13]. In
these last years tetracyclines have been found to inhibit in vitro
aggregation and disrupt amyloid fibrils of a variety of other
fibrillogenic proteins, suggesting they may be effective in other
disorders related to misfolded proteins [7,22–27]. They exert
beneficial effects in vivo in models of Parkinson’s, Huntington’s and
Alzheimer’s diseases, by inhibiting caspase-1, caspase-3, inducible
nitric oxide synthase expression and nitric oxide-mediated toxicity,
although a role of their anti-fibrillogenic efficacy cannot be ruled
out [28–30]. In these models minocycline was particularly
effective, crossing the BBB more than the other tetracyclines.
However, in a model of familial amyloidotic polyneuropathy,
doxycycline disaggregated the deposits of extracellular fibrils of
transthyretin in mice [31].
This study comprised peripheral (intramuscular and subcuta-
neous) and intracerebral administration of the 263K scrapie strain
to mimic respectively iatrogenic and sporadic forms of the disease.
The intramuscular route of infection was very efficient in
spreading the disease in the animals, confirming that skeletal
muscle has a preferential network in the propagation of the
infection. For instance, in our laboratory the median survival of
hamsters treated with the same homogenate at the dilution of 10
24
of 263 K scrapie strain was respectively 259, 234, 122 days after
ip, im and ic injection. Subcutaneous inoculation of the 263 K
scrapie strain was used as a model of penetration of PrP
Sc through
the skin mucous membranes. Subcutaneous transmission of PrP
Sc
efficiently spreads the disease in immunocompetent animals
through follicular dendritic cells in the epidermis [34]. In our
experimental model the latency of the disease was much longer
(median survival 611 days in control animals) compared to the
other routes of administration. For long-term ip treatments we
have used a dose of 10 mg/kg/day which is well tolerated by
hamsters [32,33]. Higher dose levels of 20 or 25 mg/kg/day could
not be used due to manifestation of overt toxicity and serious
inflammatory effects at the site of injection.
The effectiveness of tetracyclines after im and sc infection in
prolonging the life-span of animals suggests they may be useful
candidates for prevention strategies of acquired forms of the
disease.
Intracerebroventricular administration of quinacrine, ampho-
tericin B, pentosan polysulfate and quinoline derivatives in
transgenic mice inoculated ic with 263K, RML and Fukuoka 1
strains was carried out by Doh-ura et al. [35] and Murakami-
Kubo et al. [36] in an experimental model of prolonged infusion
lasting four weeks. The treatment with amphotericin B or
pentosan polysulfate was effective when started in early stages of
the disease and quinine had efficacy when given in a relatively late
stage of the disease.
We investigated the effectiveness of doxycycline and minocy-
cline at an advanced stage of infection, i.e. 60 days after
inoculation of 263 K scrapie strain homogenate, when 50% of
animals showed the first neurological symptoms. A single infusion
of 25 mg/20 ml icv of tetracyclines entrapped in liposomes was
used since infusion of tetracycline solutions can induce overt acute
toxicity. This enabled us to reach doxycycline and minocycline
levels of 50 mg/g in brain, well above the Cmax that can be
measured in rats after 25 mg/kg of minocycline iv [19]. The
concentration of tetracycline in liposomes infused icv was the
highest possible based upon the entrapment recovery of the drugs.
A single icv infusion of LipoDoxycycline or LipoMinocycline at
Figure 2. Effect of tetracyclines following intracerebral scrapie
infection. (A) Immunoblot analysis of 263K scrapie infected brain
homogenate (1%) after incubation in the absence (lane 1), or presence
of doxycycline (lanes 2, 3), liposome-containing doxycycline (lane 4) and
empty liposomes (lane 5), followed by proteinase K digestion. The blots
were probed with the antibody 3F4 (1:5,000). Molecular mass markers
are indicated to the left. (B) Cerebral cortex of hamster four days after
an intracerebroventricular infusion of 25 mg/20 ml liposome-containing
doxycycline. Doxycycline-related fluorescence appears to be partly
diffused in the neuropil and partly associated with nerve cell bodies and
processes (arrows) and glial cells. Magnification scale bar: 50 mm. (C)
Survival of hamsters injected intracerebrally with a 10
24 dilution of
263K scrapie-infected brain homogenate followed 60 days later by a
single intracerebroventricular infusion of 25 mg/20 ml doxycycline or
minocycline-containing liposomes. By this time 50% of infected animals
showed initial clinical symptoms of disease, i.e. hyperreactivity to tactile
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reaching statistical significance for doxycycline and close to
significance for minocycline. In our opinion this difference,
however, reflects the small number of animals in each experi-
mental group, which reduced the statistical power of the analysis,
and the lower effectiveness of minocycline in sensitizing PrP
peptides to protease hydrolysis, as shown in cell-free tests [7].
Moreover, the comparable efficacy of icv LipoDoxycycline or
LipoMinocycline indicates that the BBB is crucial in the survival of
animals treated ip. Minocycline, which is known to cross the BBB
to a greater extent than tetracycline and doxycycline, was the most
effective molecule.
Our data confirm that liposomes containing tetracyclines can be
safely administered icv and suggest that continuous infusions could
improve their therapeutic index. The development of pharma-
ceutical formulations employing liposomes or nanoparticles to
facilitate the BBB passage of these drugs might offer alternative
ways of administration such as continuous iv or ip infusions to
attain high steady-state drugs levels in the brain.
The broad efficacy of tetracyclines has to be confirmed in
different animal models and with different prion strains. In fact,
the onset and progression of the disease is variable and highly
dependent on the prion strain and host animal species considered.
The host/prion strain interaction is regulated by multiple factors,
such as accumulation and distribution of PrPSc, incubation time
and length of the disease as well as protein sensitivity to proteinase
K degradation [37,38]. The last factor is likely to be crucial in
dictating sensitivity to tetracyclines, induction of proteinase K-
dependent degradation of PrP
Sc is purported to be the major
mechanism underlying the anti-prion activity of these drugs. In
this context, it is worth mentioning that the antibiotic Amphoter-
icin B, which is known to decrease resistance to proteinase K
digestion, prolongs the lifespan of hamsters infected with the 263K
strain of PrP
Sc [39,40]. However, its therapeutic activity is limited
to this prion strain and is not observed after infection of the
animals with other strains [41]. Ongoing studies are aimed at
verifying the effectiveness of tetracycline treatment in hamsters
and mice using PrP
Sc strains with different propagation properties
and sensitivity to proteinase K action.
A further point worth exploring is the dissociation between the
anti-microbial and anti-fibrillogenic activity of tetracyclines.
Formally we have not excluded the possibility that the beneficial
effect of tetracyclines may results from other as yet unresolved
mechanisms. Though unlikely, it is possible that the increased
survival of the animals is related to antibiotic activity of
tetracyclines. As the chemical functionalities responsible of the
antibiotic activity of these drugs are known [42] we are in the
process of testing the anti-prion properties of tetracyclines devoid
of anti-microbial activity.
In conclusion this study found that tetracyclines can counteract
the onset and progression of prion disease and might therefore be
potentially useful for human therapy. In the last five years, a small
group of CJD patients has received compassionate treatment with
daily doses of 100 mg/kg doxycycline, and retrospective analysis
showed significantly longer survival than untreated patients
(Tagliavini F, et al., manuscript in preparation). Once again
whether this effect is related to anti-prion activity or to protection
of patients from bacterial infection is yet to be established. A major
limitation of this study is that the results are not the outcome of a
formal clinical trial but are based on open observations. The data
reported in this paper provided the experimental basis for an
ongoing Italian phase II, multicenter, randomized, double-blind,
placebo-controlled efficacy study of doxycycline in CJD patients
funded by the Italian Drug Agency.
Materials and Methods
Prion transmission
Male Golden Syrian hamsters (Charles River, Calco, Lecco,
Italy), 6–8 weeks old, were im (in the posteriour leg) or sc (under
the skin of the back) infected with 100 ml of 263K scrapie strain at
a1 0
24 dilution from scrapie-infected hamster brains at the
terminal stage of disease. Other hamsters were infected ic with
20 ml of the same scrapie strain. Each experimental group
consisted of 10–12 animals.
Tetracycline hydrochloride (Fluka, Switzerland), doxycycline
hyclate and minocycline hydrochloride (Sigma Aldrich, Switzer-
land) were freshly dissolved in saline before ip administration.
After prion infection, ten animals per group were treated
according to the schedules summarized in Table 1. Doxycycline
was injected im, 10 mg/kg, 1 hour after im prion infection.
Doxycycline, minocycline or tetracycline were injected ip, 10 mg/
kg, 1 hour after im prion infection then every two days for
40 days, or from 4 to 44 days after sc prion infection. Ic infected
hamsters were anesthetized with chloral hydrate (Merck, Ger-
many) and a polyethylene cannula was permanently implanted
into the lateral ventricle opposite to the hemisphere injected with
263K brain homogenate. Then a suspension 20 ml of liposomes
containing 25 mg of doxycycline or minocycline were infused icv
when the first symptoms of infection appeared (60 days) in 50% of
hamsters (hyperreactivity to tactile and acoustic stimulation). Non-
infected control animals were treated with liposomes containing
tetracyclines.
Animals were housed in groups of 3–4 in a temperature-
controlled (2062uC) quarantined room maintained on a 12-hour
light-dark cycle. They were allowed free access to food and water
and were observed once a week until terminal stage of the disease
to record the onset and progression of clinical signs. Behavioural
analysis included evaluation of their reactivity to tactile and
acoustic stimulation, posture, balance and coordination, and the
onset of tremors [17].
Procedures involving animals and their care were conducted in
conformity with national and international laws and policies (EEC
Council Directive 86609, OJ L358, 1, 12 December 1987; Italian
Legislative Decree 116/92, Gazzetta Ufficiale della Repubblica
Italiana n.10, 18 February 1992; Guide for the Care and Use of
Laboratory Animals, US National Research Council, 1996).
Preparation of liposome-containing tetracyclines
Doxycycline and minocycline were entrapped in neutral
multilamellar liposomes (LipoDoxycycline and LipoMinocycline)
made up of phosphatidylcholine and cholesterol (7:1, molar ratio)
[18]. Empty liposomes were made of phosphatidylcholine and
cholesterol alone. The concentration of drug entrapped in
liposomes was determined by HPLC [19] and the entrapment
efficiency was 5% for both tetracyclines (mean of five prepara-
tions). Liposomes were stable for at least two weeks at 4uC in the
dark.
Brain distribution of liposome-containing doxycycline
To determine the brain distribution of LipoDoxycycline and
empty liposomes, hamsters were icv treated as described above
and killed four days later. Brains were dissected and 20 mm
cryostat sections were prepared. No significant fluorescence signals
were detected in the brain injected with empty liposomes. Drug
distribution was evaluated by determining doxycycline fluores-
cence in coronal sections with a microscope (Olympus BX51) at
400–440 nm excitation and 475 nm emission.
Tetracycline Anti-Prion Action
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Sc protease-resistance by liposome-
containing doxycycline
To investigate whether LipoDoxycycline was as effective as free
doxycycline during the PrP
Sc folding, 1% 263K brain homogenate
(10
22 dilution) was incubated for 24 hours at 37uC in the presence
of doxycycline (25–100 mg), LipoDoxycycline (25 mg) or the same
volume of empty liposomes. Samples were then treated for 1 hour
at 37uC with 10 mg/ml of PK (Roche, Switzerland). The amount
of PrP
Sc remaining after proteolysis was assessed by Western blot
analysis as described by Tagliavini et al. [13].
Immunohistochemical studies
At autopsy, the left lateral two-third of each hamster brain, one
half of the spleen, a fraction of the small intestine at the level of
Peyer’s patches and the spinal cord were dissected and immediately
fixed for 24 hours in Carnoy solution at 4uC [20]. The fixed brains
were then dissected at four standard coronal levels. All fixed tissues
were dehydrated, embedded in Paraplast and 5-mm thick serial
sections were stained with hematoxylin-eosin. PrP
Sc immunohisto-
chemistry was carried out using monoclonal antibody 3F4 (1:1000
dilution, Dako, Denmark) which recognized an epitope including
residues 109 to 112 of hamster PrP. Before immunostaining,
sections were treated with 10 mg/ml of PK for 5 min then with 3M
guanidine thiocyanate for 30 min [20]. Immunoreactions were
revealed with the monoclonal EnVision system (Dako, Denmark)
using 3-39-diamonobenzidine as chromogen.
Statistical analysis
Survival times were analyzed by Kaplan-Meier Survival
Analysis using the log-rank test to compare the curves. Statistical
analysis was done using Prism version 4.0 for Windows (GraphPad
Software, San Diego, CA).
Acknowledgments
Author Contributions
Conceived and designed the experiments: FT RC GF MS AD LC.
Performed the experiments: RC MM CM AD LC LD LL. Analyzed the
data: FT RC MM CM MS AD LC LD LL. Wrote the paper: MS AD.
References
1. Prusiner SB (2001) Shattuck lecture–neurodegenerative diseases and prions.
N Engl J Med 344: 1516–1526.
2. Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95: 13363–13383.
3. Riesner D (2003) Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull
66: 21–33.
4. Korth C, Peters PJ (2006) Emerging pharmacotherapies for Creutzfeldt-Jakob
disease. Arch Neurol 63: 497–501.
5. Caramelli M, Ru G, Acutis P, Forloni G (2006) Prion diseases: current
understanding of epidemiology and pathogenesis, and therapeutic advances.
CNS Drugs 20: 15–28.
6. Weissmann C, Aguzzi A (2005) Approaches to therapy of prion diseases. Annu
Rev Med 56: 321–344.
7. Forloni G, Varı ` MR, Colombo L, Bugiani O, Tagliavini F, et al. (2003) Prion
disease: time for a therapy ? Curr Med Chem-Immun, Endoc & Metab Agents 3:
185–197.
8. Todd NV, Morrow J, Doh-ura K, Dealler S, O’Hare S, et al. (2005)
Cerebroventricular infusion of pentosan polysulphate in human variant
Creutzfeldt-Jakob disease. J Infect 50: 394–396.
9. Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-ura K (2007)
Experimental treatments for human transmissible spongiform encephalopathies:
is there a role for pentosan polysulfate? Expert Opin Biol Ther 7: 713–726.
10. Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi M, et al. (2004)
Results of quinacrine administration to patients with Creutzfeldt-Jakob disease.
Dement Geriatr Cogn Disord 17: 158–163.
11. Benito-Leon J (2004) Combined quinacrine and chlorpromazine therapy in fatal
familial insomnia. Clin Neuropharmacol 27: 201–203.
12. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, et al. (2004) Efficacy of
flupirtine on cognitive function in patients with CJD: A double-blind study.
Neurology 62: 714–718.
13. Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, et al. (2000)
Tetracycline affects abnormal properties of synthetic PrP peptides and PrP
(Sc) in vitro. J Mol Biol 300: 1309–1322.
14. Domercq M, Matute C (2004) Neuroprotection by tetracyclines. Trends
Pharmacol Sci 25: 609–612.
15. Cosentino U, Varı ` MR, Saracino AA, Pitea D, Moro G, et al. (2005)
Tetracycline and its analogues as inhibitors of amyloid fibrils: searching for a
geometrical pharmacophore by theoretical investigation of their conformational
behavior in aqueous solution. J Mol Model 11: 17–25.
16. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, et al. (2002)
Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 99:
10849–10854.
17. Tagliavini F, McArthur RA, Canciani B, Giaccone G, Porro M, et al. (1997)
Effectiveness of anthracycline against experimental prion disease in Syrian
hamsters. Science 276: 1119–1122.
18. Konings AWT (1984) Lipid peroxidation in liposome. In: Gregoriadis G, ed.
Liposome technology. Boca Raton: CRC Press. pp 139–161.
19. Colovic M, Caccia S (2003) Liquid chromatographic determination of minocycline
in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol
Biomed Life Sci 791: 337–343.
20. Giaccone G, Canciani B, Puoti G, Rossi G, Goffredo D, et al. (2000)
Creutzfeldt-Jakob disease: Carnoy’s fixative improves the immunohistochemistry
of the proteinase K-resistant prion protein. Brain Pathol 10: 31–37.
21. Ragg E, Tagliavini F, Malesani P, Monticelli L, Bugiani O, et al. (1999)
Determination of solution conformations of PrP106-126, a neurotoxic fragment
of prion protein, by 1H NMR and restrained molecular dynamics. Eur J Biochem
266: 1192–1201.
22. Malmo C, Vilasi S, Iannuzzi C, Tacchi S, Cametti C, et al. (2006) Tetracycline
inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein
in a pre-fibrillar, highly cytotoxic state. FASEB J 20: 346–347.
23. Ono K, Yamada M (2006) Antioxidant compounds have potent anti-
fibrillogenic and fibril- destabilizing effects for alpha-synuclein fibrils in vitro.
J Neurochem 97: 105–115.
24. Aitken JF, Loomes KM, Konarkowska B, Cooper GJ (2003) Suppression by
polycyclic compounds of the conversion of human amylin into insoluble
amyloid. Biochem J 374: 779–784.
25. Cardoso I, Merlini G, Saraiva MJ (2003) 49-iodo-49-deoxydoxorubicin and
tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic
species: screening for TTR fibril disrupters. FASEB J 17: 803–809.
26. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, et al. (2003)
Minocycline and doxycycline are not beneficial in a model of Huntington’s
disease. Ann Neurol 54: 186–196.
27. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M (2001) Anti-
amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487: 404–407.
28. Du Y, Ma Z, Lin S, Dodel RC, Gao F, et al. (2001) Minocycline prevents
nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkin-
son’s disease. Proc Natl Acad Sci U S A 98: 14669–14674.
29. Hersch S, Fink K, Vonsattel JP, Friedlander RM (2003) Minocycline is
protective in a mouse model of Huntington’s disease. Ann Neurol 54: 841.
30. Seabrook TJ, Jiang L, Maier M, Lemere CA (2006) Minocycline affects
microglia activation, Abeta deposition, and behavior in APP -tg mice. Glia 53:
776–782.
31. Cardoso I, Saraiva MJ (2006) Doxycycline disrupts transthyretin amyloid:
evidence from studies in a FAP transgenic mice model. FASEB J 20: 234–239.
32. Moon JE, Ellis MW, Griffith ME, Hawley JS, Rivard RG, et al. (2006) Efficacy
of macrolides and telithromycin against leptospirosis in a hamster model.
Antimicrob Agents Chemother 50: 1989–1992.
33. Truccolo J, Charavay F, Merien F, Perolat P (2002) Quantitative PCR assay to
evaluate ampicillin, ofloxacin, and doxycycline for treatment of experimental
leptospirosis. Antimicrob Agents Chemother 46: 848–853.
34. Mohan J, Bruce ME, Mabbott NA (2005) Follicular dendritic cell dedifferen-
tiation reduces scrapie susceptibility following inoculation via the skin.
Immunology 114: 225–234.
35. Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, et al. (2004)
Treatment of transmissible spongiform encephalopathy by intraventricular drug
infusion in animal models. J Virol 78: 4999–5006.
36. Murakami-Kubo I, Doh-Ura K, Ishikawa K, Kawatake S, Sasaki K, et al. (2004)
Quinoline derivatives are therapeutic candidates for transmissible spongiform
encephalopathies. J Virol 78: 1281–1288.
37. Clarke AR, Jackson GS, Collinge J (2001) The molecular biology of prion
propagation. Philos Trans R Soc Lond B Biol Sci. 356: 185–195.
38. Bruce ME (2003) TSE strain variation. Br Med Bull 66: 99–108.
39. Demaimay R, Adjou K, Lasme ´zas C, Lazarini F, Cherifi K, Seman M,
Deslys JP, Dormont D (1994) Pharmacological studies of a new derivative of
amphotericin B, MS-8209, in mouse and hamster scrapie. J Gen Virol 75:
2499–2503.
40. Adjou KT, Privat N, Demart S, Deslys JP, Seman M, Hauw JJ, Dormont D
(2000) MS-8209, an amphotericin B analogue, delays the appearance of
Tetracycline Anti-Prion Action
PLoS ONE | www.plosone.org 6 March 2008 | Volume 3 | Issue 3 | e1888spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected
hamsters. J Comp Pathol 122: 3–8.
41. Demaimay R, Race R, Chesebro B (1999) Effectiveness of polyene antibiotics in
treatment of transmissible spongiform encephalopathy in transgenic mice
expressing Syrian hamster PrP only in neurons. J Virol 7: 3511–3513.
42. Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action,
applications, molecular biology, and epidemiology of bacterial resistance.
Microbiol Mol Biol Rev 65: 232–260.
Tetracycline Anti-Prion Action
PLoS ONE | www.plosone.org 7 March 2008 | Volume 3 | Issue 3 | e1888